Vascular Biogenics Ltd (VBLT) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $11. H.C. Wainwright advised their investors in a research report released on Jun 28, 2016.
Vascular Biogenics Ltd closed down -0.13 points or -3.19% at $3.95 with 2,80,884 shares getting traded on Monday. Post opening the session at $4.07, the shares hit an intraday low of $3.81 and an intraday high of $4.2 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. The Company is developing VB-111 the lead oncology product candidate from its VTS platform technology which is a gene-based biologic for the treatment of solid tumor indications with clinical programs in recurrent glioblastoma (rGBM) thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.